Observational Cohort Study of TachoSil (TC-018-IN)

Nycomed3,000 enrolled

Overview

The purpose of this study is to collect information, after exposure to TachoSil ®, of all thromboembolic events, immunological events and drug interactions leading to thromboembolic events or major bleeding. In addition, pharmacoeconomic data will be collected.

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

Blood Loss, Surgical

Interventions

Fibrinogen (human) + thrombin (human) (TachoSil)DRUG

treatment in surgery for improvement of haemostasis where standard techniques are insufficient

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All subjects, treated with TachoSil ® by the participating physicians, will be registered with a set of basic data from their already existing data (i.e. no additional diagnostic procedures will be performed). * Subjects who will provide their written informed consent to use existing data, allow direct access to data and data processing.

Locations (1)

Nycomed

Roskilde, Denmark

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.